A Phase 1/2 interventional study of MRT5005 and Normal saline in Cystic Fibrosis, sponsored by Sanofi. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 230th largest by enrollment of the 517 interventional ones that give a count, is one of 39 that started in 2018, is one of 32 in phase 1/2, and was the 442nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 39 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of CF as defined by both of the following:
Exclusion Criteria:
Treatment with ORKAMBI or SYMDEKO was not an exclusion for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of MRT5005 8 milligrams (mg) by nebulization on Day 1.
Drug: MRT5005
Participants received single dose of MRT5005 16 mg by nebulization on Day 1.
Drug: MRT5005
Participants received single dose of MRT5005 20 mg by nebulization on Day 1.
Drug: MRT5005
Participants received single dose of MRT5005 24 mg by nebulization on Day 1.
Drug: MRT5005
Participants received single dose of placebo (normal saline) by nebulization on Day 1. Data were analyzed as a pooled population for all participants who received placebo in Part A SAD groups and reported in this arm.
Drug: Normal saline
Participants received MRT5005 8 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).
Drug: MRT5005
Participants received MRT5005 12 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).
Drug: MRT5005
Participants received MRT5005 16 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).
Drug: MRT5005
Participants received MRT5005 20 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).
Drug: MRT5005
Participants received placebo (normal saline) once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29). Data were analyzed as a pooled population for all participants who received placebo in Part B MAD groups and reported in this arm.
Drug: Normal saline
Participants received MRT5005 4 mg once daily by nebulization from Day 1 to Day 5.
Drug: MRT5005
Participants received placebo (normal saline) once daily by nebulization from Day 1 to Day 5.
Drug: Normal saline
Nebulization of MRT5005
Normal Saline for Inhalation
Parts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily had a causal relationship with the study treatment. A serious adverse event (SAE) was any untoward medical occurrence (whether considered to be related to study treatment or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital abnormality/birth defect; or was an important medical event. The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study treatment up to 48 weeks (end of follow-up period) after the last dose of study treatment administration.
Time frame: From the first dose of study treatment administration (Day 1) up to 48 weeks (end of the follow-up period) after the last dose of study treatment administration (Part A: Day 337, Part B: Day 365 and Part D: Day 341)
Parts A, B and D: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Spirometry was performed according to the guidelines published by the American Thoracic Society for standardization of spirometry. The ppFEV1 was assessed during the spirometry testing. For Parts A and B, the baseline value was defined as the average of the results from testing on Day -1 and at pre-dose on Day 1. For Part D, the baseline value was defined as the result from testing pre-dose on Day 1. Here, Baseline= BL, Day= D, pre-dose= PrD, hours post dose= hPD.
Time frame: Part A:BL, D1(8hPD), D2(24hPD), D3, D8, D15 and D29; Part B:BL, D1(6hPD), D2, D8(PrD and 6hPD), D9, D15(PrD and 6hPD), D16, D22(PrD and 6hPD), D23, D29(PrD and 6hPD), D30, D36, D43 and D57; Part D:BL, D1(2hPD), PrD on D2, D3, D4 and D5, D11, D18 and D32
The study was conducted at 16 active centers. A total of 53 participants were screened from 10 May 2018 to 22 February 2021, of which 11 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
| Milestone | Part A - SAD Group 1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 4: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 5 | 6 | 2 |
| Completed | 3 | 3 | 2 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 2 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Site closure due to coronavirus disease 2019 pandemic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily had a causal relationship with the study treatment. A serious adverse event (SAE) was any untoward medical occurrence (whether considered to be related to study treatment or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital abnormality/birth defect; or was an important medical event. The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study treatment up to 48 weeks (end of follow-up period) after the last dose of study treatment administration.
| Participants | Part A - SAD Group 1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 4: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 5 | 6 | 2 |
| Any Serious TEAE | 0 | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 2 | 2 | 1 | 1 |
Spirometry was performed according to the guidelines published by the American Thoracic Society for standardization of spirometry. The ppFEV1 was assessed during the spirometry testing. For Parts A and B, the baseline value was defined as the average of the results from testing on Day -1 and at pre-dose on Day 1. For Part D, the baseline value was defined as the result from testing pre-dose on Day 1. Here, Baseline= BL, Day= D, pre-dose= PrD, hours post dose= hPD.
| percent predicted FEV1 | Part A - SAD Group 1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 4: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: 2 hours post-dose | — | — | — | — | — | — | — | — | — | — | 5.1117 ± 3.75481 | -2.4150 ± 1.23744 |
| Day 1: 6 hours post-dose | — | — | — | — | — | -2.7017 ± 3.37188 | -0.3417 ± 2.17959 | -0.0062 ± 2.66067 | -1.9533 ± 8.52538 | 1.8400 ± 4.62365 | — | — |
| Day 1: 8 hours post-dose | 3.6550 ± 0.94230 | 7.2233 ± 7.29017 | 1.1067 ± 1.91247 | 2.4525 ± 0.44194 | 1.1088 ± 3.58541 | — | — | — | — | — | — | — |
| Day 2: Pre-dose | — | — | — | — | — | — | — | — | — | — | 3.7300 ± 6.24287 | -0.1600 ± 4.11536 |
| Day 2 | 2.7750 ± 1.84369 | 11.2100 ± 10.32509 | 4.0967 ± 4.74504 | 8.6233 ± 11.20869 | 0.1863 ± 2.04118 | -2.2383 ± 2.84509 | -0.2317 ± 0.75466 | 1.7013 ± 2.56612 | 2.0067 ± 2.48702 | 2.2360 ± 4.56081 | — | — |
| Day 3: Pre-dose | — | — | — | — | — | — | — | — | — | — | 2.7583 ± 7.60588 | -1.8350 ± 0.65761 |
| Day 3 | 3.4183 ± 2.29152 | 11.3767 ± 5.14516 | 2.3700 ± 5.72278 | 6.5800 ± 4.81868 | -1.6687 ± 3.21471 | — | — | — | — | — | — | — |
| Day 4: Pre-dose | — | — | — | — | — | — | — | — | — | — | 1.8367 ± 7.00783 | 2.0050 ± 3.38704 |
| Day 5: Pre-dose | — | — | — | — | — | — | — | — | — | — | 2.7833 ± 5.62575 | 0.9100 ± 4.53963 |
| Day 8: Pre-dose | — | — | — | — | — | -0.9883 ± 0.65929 | -0.8617 ± 2.50250 | 1.9033 ± 3.87243 | -5.0133 ± 6.39082 | 4.8563 ± 3.87653 | — | — |
| Day 8: 6 hours post-dose | — | — | — | — | — | -3.0250 ± 2.66540 | 0.7650 ± 4.12427 | 2.6400 ± 3.60712 | -5.2500 ± 13.55809 | 1.7488 ± 4.61824 | — | — |
| Day 8 | -1.2350 ± 3.02842 | 9.1867 ± 1.78340 | 0.8533 ± 0.96144 | 2.2867 ± 3.15587 | -0.9512 ± 3.31965 | — | — | — | — | — | — | — |
| Day 9 | — | — | — | — | — | -0.2550 ± 3.32058 | -1.9250 ± 1.44439 | 0.9800 ± 2.77307 | -0.3067 ± 3.83939 | 2.4963 ± 3.58692 | — | — |
| Day 11 | — | — | — | — | — | — | — | — | — | — | 1.0567 ± 2.53699 | -0.8450 ± 3.14663 |
| Day 15: Pre-dose | — | — | — | — | — | 1.4783 ± 4.88812 | -2.2750 ± 3.35929 | 3.2767 ± 2.85037 | -7.0867 ± 3.29160 | 0.2438 ± 4.78050 | — | — |
| Day 15: 6 hours post-dose | — | — | — | — | — | -1.9083 ± 4.30519 | -0.8350 ± 0.48210 | 3.5100 ± 2.36540 | -3.0233 ± 10.09021 | 3.6763 ± 2.82176 | — | — |
| Day 15 | -0.2383 ± 3.63470 | 5.5633 ± 1.21378 | -2.3233 ± 1.80292 | 0.4833 ± 5.25663 | 0.5763 ± 1.57608 | — | — | — | — | — | — | — |
| Day 16 | — | — | — | — | — | -2.6017 ± 3.59609 | -4.4217 ± 0.24322 | 1.6800 ± 1.39796 | -3.9033 ± 6.24793 | 2.5388 ± 5.43594 | — | — |
| Day 18 | — | — | — | — | — | — | — | — | — | — | 0.1600 ± 1.78332 | -1.3700 ± 0.77782 |
| Day 22: Pre-dose | — | — | — | — | — | -3.4417 ± 0.79907 | -2.5317 ± 3.12407 | 1.0433 ± 2.61190 | -3.5567 ± 3.44181 | 1.6863 ± 6.44122 | — | — |
| Day 22: 6 hours post-dose | — | — | — | — | — | -4.4150 ± 1.30844 | -3.1183 ± 2.60335 | 1.4033 ± 2.70263 | -3.2933 ± 8.33613 | 4.9788 ± 8.56683 | — | — |
| Day 23 | — | — | — | — | — | -2.5650 ± 2.27414 | -3.5550 ± 1.42163 | 2.6233 ± 5.05601 | -3.1900 ± 6.42324 | 0.7463 ± 8.20475 | — | — |
| Day 29: Pre-dose | — | — | — | — | — | -4.1350 ± 1.25896 | -2.9725 ± 3.42593 | 0.1667 ± 1.82582 | -5.7133 ± 2.39036 | 2.9863 ± 9.33491 | — | — |
| Day 29: 6 hours post-dose | — | — | — | — | — | -4.7350 ± 0.70326 | 0.3125 ± 0.06010 | 0.8467 ± 1.79528 | 0.0567 ± 11.03200 | 2.7563 ± 4.51659 | — | — |
| Day 29 | 3.0983 ± 4.90188 | 4.6633 ± 4.65445 | 2.5133 ± 5.06806 | -5.2633 ± 13.06648 | 0.7517 ± 4.27498 | — | — | — | — | — | — | — |
| Day 30 | — | — | — | — | — | -3.2717 ± 4.61490 | -4.7375 ± 3.98455 | 4.8000 ± 5.94778 | 1.1667 ± 8.98756 | 0.9888 ± 7.33033 | — | — |
| Day 32 | — | — | — | — | — | — | — | — | — | — | 4.8550 ± 6.05264 | -0.1150 ± 4.49013 |
| Day 36 | — | — | — | — | — | -0.9383 ± 2.30022 | -2.2975 ± 2.85318 | -0.7733 ± 5.20926 | -3.5333 ± 8.93039 | 4.8463 ± 8.26378 | — | — |
| Day 43 | — | — | — | — | — | -3.2550 ± 0.69262 | -0.0050 | -2.0367 ± 6.75614 | -3.1533 ± 3.50810 | 5.1363 ± 7.51406 | — | — |
| Day 57 | — | — | — | — | — | -5.5517 ± 4.38918 | 1.0750 | 1.9500 ± 1.02103 | -7.1667 ± 9.31929 | 0.4288 ± 5.91134 | — | — |
Collected over Serious adverse events (AEs), other AEs and all-cause mortality (deaths) were collected from the first dose of study treatment administration (Day 1) up to 48 weeks (end of the follow-up period) after the last dose of study treatment administration (Part A: Day 337, Part B: Day 365 and Part D: Day 341). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - SAD Group1: MRT5005 8 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A - SAD Group 2: MRT5005 16 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A - SAD Group 3: MRT5005 20 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - SAD Group 4: MRT5005 24 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - SAD Groups: Pooled Placebo | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Part B - MAD Group 1: MRT5005 8 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part B - MAD Group 2: MRT5005 12 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part B - MAD Group 3: MRT5005 16 mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part B - MAD Group 3: MRT5005 20 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part B - MAD Groups: Pooled Placebo | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Part D: MRT5005 4 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Part D: Placebo | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Part A - SAD Group1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 3: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infective Pulmonary Exacerbation Of Cystic FibrosisInfections and infestations | 0/3 | 0/3 | 1/3 | 1/3 | 2/4 | 1/3 | 0/3 | 0/4 | 1/3 | 2/5 | 1/6 | 1/2 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/3 | 0/4 | 1/3 | 0/5 | 0/6 | 0/2 |
| Calculus UrinaryRenal and urinary disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/3 | 0/4 | 1/3 | 0/5 | 0/6 | 0/2 |
| Femoral Neck FractureInjury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 1/3 | 0/4 | 0/3 | 0/5 | 0/6 | 0/2 |
| Cholecystitis AcuteHepatobiliary disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | 0/3 | 0/4 | 0/3 | 0/5 | 0/6 | 0/2 |
| Anaphylactic ReactionImmune system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/3 | 0/4 | 0/3 | 0/5 | 1/6 | 0/2 |
| Event | Part A - SAD Group1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 3: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infective Pulmonary Exacerbation Of Cystic FibrosisInfections and infestations | 3/3 | 2/3 | 3/3 | 3/3 | 3/4 | 3/3 | 0/3 | 2/4 | 0/3 | 2/5 | 3/6 | 1/2 |
| HeadacheNervous system disorders | 2/3 | 3/3 | 1/3 | 3/3 | 1/4 | 1/3 | 1/3 | 1/4 | 3/3 | 1/5 | 2/6 | 0/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/3 | 2/3 | 1/3 | 3/3 | 0/4 | 3/3 | 2/3 | 4/4 | 1/3 | 3/5 | 2/6 | 2/2 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 3/3 | 0/4 | 0/3 | 1/3 | 1/4 | 1/3 | 0/5 | 0/6 | 0/2 |
| PyrexiaGeneral disorders | 1/3 | 2/3 | 0/3 | 3/3 | 0/4 | 0/3 | 1/3 | 3/4 | 2/3 | 0/5 | 0/6 | 0/2 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 2/3 | 1/3 | 3/4 | 0/3 | 0/3 | 2/4 | 1/3 | 2/5 | 1/6 | 0/2 |
| ChillsGeneral disorders | 1/3 | 1/3 | 0/3 | 2/3 | 0/4 | 1/3 | 1/3 | 3/4 | 2/3 | 0/5 | 1/6 | 0/2 |
| SinusitisInfections and infestations | 0/3 | 2/3 | 1/3 | 1/3 | 1/4 | 1/3 | 0/3 | 1/4 | 0/3 | 2/5 | 0/6 | 1/2 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/3 | 1/3 | 1/3 | 1/3 | 1/4 | 1/3 | 0/3 | 0/4 | 2/3 | 0/5 | 1/6 | 1/2 |
| DizzinessNervous system disorders | 1/3 | 1/3 | 0/3 | 1/3 | 1/4 | 2/3 | 0/3 | 0/4 | 0/3 | 2/5 | 1/6 | 0/2 |
The Safety analysis set included all randomized participants who received study treatment.
| Age, Categorical(Participants) | Part A - SAD Group 1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 4: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 4 | 6 | 2 | 41 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Part A - SAD Group 1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 4: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 1 | 2 | 3 | 1 | 3 | 1 | 3 | 5 | 1 | 23 |
| Male | 3 | 2 | 1 | 2 | 2 | 0 | 2 | 1 | 2 | 2 | 1 | 1 | 19 |
| Race/Ethnicity, Customized(Participants) | Part A - SAD Group 1: MRT5005 8 mg | Part A - SAD Group 2: MRT5005 16 mg | Part A - SAD Group 3: MRT5005 20 mg | Part A - SAD Group 4: MRT5005 24 mg | Part A - SAD Groups: Pooled Placebo | Part B - MAD Group 1: MRT5005 8 mg | Part B - MAD Group 2: MRT5005 12 mg | Part B - MAD Group 3: MRT5005 16 mg | Part B - MAD Group 4: MRT5005 20 mg | Part B - MAD Groups: Pooled Placebo | Part D: MRT5005 4 mg | Part D: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 5 | 6 | 2 | 41 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from May 2018 to primary completion in Mar 2022, 46 months.
Results were first posted in Feb 2026, 3 years 10 months after primary completion.
Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 46 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.